Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 1.655 AUD 0.61% Market Closed
Market Cap: 2.1B AUD

Wall Street
Price Targets

MSB Price Targets Summary
Mesoblast Ltd

Wall Street analysts forecast MSB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MSB is 2.958 AUD with a low forecast of 2.424 AUD and a high forecast of 3.57 AUD.

Lowest
Price Target
2.424 AUD
46% Upside
Average
Price Target
2.958 AUD
79% Upside
Highest
Price Target
3.57 AUD
116% Upside
Mesoblast Ltd Competitors:
Price Targets
688293
Shanghai OPM Biosciences Co Ltd
3% Upside
VITR
Vitrolife AB
50% Upside
2696
Shanghai Henlius Biotech Inc
32% Downside
HALO
Halozyme Therapeutics Inc
26% Upside
HLVX
Hillevax Inc
2% Downside
PHM
Pharma Mar SA
18% Upside
AMRN
Amarin Corporation PLC
19% Downside
TLX
Telix Pharmaceuticals Ltd
43% Upside

Revenue
Forecast

Revenue Estimate
Mesoblast Ltd

For the last 8 years the compound annual growth rate for Mesoblast Ltd's revenue is -22%. The projected CAGR for the next 4 years is 227%.

-22%
Past Growth
227%
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Mesoblast Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-14%
Average Miss

Net Income
Forecast

Net Income Estimate
Mesoblast Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MSB's stock price target?
Price Target
2.958 AUD

According to Wall Street analysts, the average 1-year price target for MSB is 2.958 AUD with a low forecast of 2.424 AUD and a high forecast of 3.57 AUD.

What is Mesoblast Ltd's Revenue forecast?
Projected CAGR
227%

For the last 8 years the compound annual growth rate for Mesoblast Ltd's revenue is -22%. The projected CAGR for the next 4 years is 227%.

Back to Top